Mainpointe Company Profile
What is the competitive landscape for MAINPOINTE
MAINPOINTE has one approved drug.
There are two US patents protecting MAINPOINTE drugs.
Drugs and US Patents for Mainpointe
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mainpointe | TUXARIN ER | chlorpheniramine maleate; codeine phosphate | TABLET, EXTENDED RELEASE;ORAL | 206323-001 | Jun 22, 2015 | RX | No | No | 9,107,921 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Mainpointe | TUXARIN ER | chlorpheniramine maleate; codeine phosphate | TABLET, EXTENDED RELEASE;ORAL | 206323-001 | Jun 22, 2015 | RX | No | No | 9,066,942 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Mainpointe
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mainpointe | TUXARIN ER | chlorpheniramine maleate; codeine phosphate | TABLET, EXTENDED RELEASE;ORAL | 206323-001 | Jun 22, 2015 | 6,248,363 | ⤷ Start Trial |
| Mainpointe | TUXARIN ER | chlorpheniramine maleate; codeine phosphate | TABLET, EXTENDED RELEASE;ORAL | 206323-001 | Jun 22, 2015 | 6,383,471 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

